| Code | Description | Claims | Beneficiaries | Total Paid |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
53,968 |
50,509 |
$4.04M |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
24,292 |
22,375 |
$1.96M |
| 84443 |
Thyroid stimulating hormone (TSH) |
84,587 |
76,974 |
$1.34M |
| 80053 |
Comprehensive metabolic panel |
133,487 |
119,893 |
$1.30M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
26,630 |
24,644 |
$1.21M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
26,186 |
24,314 |
$1.19M |
| 87481 |
|
9,584 |
8,503 |
$813K |
| 80061 |
Lipid panel |
98,190 |
89,254 |
$745K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
133,400 |
120,036 |
$729K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
24,518 |
21,638 |
$687K |
| 81513 |
|
7,376 |
6,697 |
$621K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
26,132 |
25,004 |
$612K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
36,633 |
33,760 |
$609K |
| 80050 |
General health panel |
12,194 |
12,039 |
$600K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
12,284 |
10,996 |
$510K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
77,689 |
71,355 |
$461K |
| 86480 |
|
7,226 |
6,773 |
$367K |
| 0001A |
|
8,779 |
8,732 |
$350K |
| 86803 |
|
18,801 |
17,053 |
$308K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
10,618 |
9,976 |
$299K |
| 0002A |
|
7,281 |
7,253 |
$297K |
| 87563 |
|
14,318 |
12,557 |
$294K |
| 91322 |
|
2,463 |
2,021 |
$290K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
15,742 |
14,892 |
$286K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
27,818 |
25,206 |
$280K |
| 86003 |
|
3,009 |
2,935 |
$228K |
| 82607 |
|
17,009 |
15,434 |
$193K |
| 84439 |
|
22,667 |
20,832 |
$192K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,974 |
3,865 |
$177K |
| 0124A |
|
4,165 |
3,974 |
$164K |
| 82728 |
|
20,221 |
18,467 |
$160K |
| 86235 |
|
1,914 |
1,787 |
$160K |
| 83550 |
|
18,874 |
17,374 |
$154K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
19,478 |
18,262 |
$147K |
| 87507 |
|
439 |
418 |
$144K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
4,620 |
4,478 |
$139K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,091 |
2,996 |
$135K |
| 0071A |
|
3,169 |
3,128 |
$134K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
388 |
380 |
$129K |
| 87340 |
|
9,598 |
8,725 |
$126K |
| 82746 |
|
11,350 |
10,305 |
$123K |
| 82570 |
|
28,324 |
26,141 |
$122K |
| 83540 |
|
20,001 |
18,361 |
$121K |
| 0072A |
|
2,806 |
2,778 |
$118K |
| 85027 |
|
20,942 |
18,940 |
$115K |
| 83880 |
|
5,168 |
4,603 |
$110K |
| 86780 |
|
6,383 |
5,904 |
$109K |
| 86706 |
|
7,830 |
7,238 |
$107K |
| 87480 |
|
3,666 |
3,314 |
$95K |
| 87510 |
|
3,619 |
3,266 |
$93K |
| 82043 |
|
23,622 |
21,856 |
$86K |
| 86787 |
|
5,588 |
5,445 |
$83K |
| 84153 |
|
6,552 |
5,971 |
$82K |
| 87529 |
|
967 |
885 |
$82K |
| 0054A |
|
1,921 |
1,912 |
$79K |
| 83970 |
|
2,862 |
2,807 |
$78K |
| 86038 |
|
5,141 |
4,782 |
$78K |
| 0004A |
|
2,153 |
1,569 |
$76K |
| 87186 |
|
6,889 |
6,449 |
$75K |
| 87081 |
|
12,608 |
11,982 |
$72K |
| 83655 |
|
5,963 |
5,901 |
$70K |
| 83013 |
|
1,816 |
1,697 |
$70K |
| 83001 |
|
3,911 |
3,552 |
$69K |
| 86592 |
|
17,156 |
15,763 |
$68K |
| 80081 |
|
1,111 |
1,007 |
$67K |
| 81001 |
|
24,267 |
22,102 |
$65K |
| 83735 |
|
10,936 |
8,685 |
$65K |
| 84403 |
|
2,593 |
2,494 |
$63K |
| 86704 |
|
4,184 |
3,841 |
$63K |
| 88342 |
|
1,213 |
1,156 |
$60K |
| 86850 |
|
10,127 |
9,258 |
$60K |
| 82274 |
|
6,377 |
6,076 |
$60K |
| 87660 |
|
3,556 |
3,213 |
$59K |
| 0011A |
|
1,471 |
1,470 |
$58K |
| 82105 |
|
3,583 |
3,450 |
$57K |
| 0012A |
|
1,380 |
1,379 |
$57K |
| 86140 |
|
12,328 |
11,516 |
$55K |
| 82784 |
|
4,109 |
3,868 |
$54K |
| 0051A |
|
1,330 |
1,308 |
$54K |
| 84481 |
|
5,541 |
4,984 |
$53K |
| 80074 |
|
1,417 |
1,298 |
$52K |
| 0111A |
|
1,213 |
1,200 |
$51K |
| 88341 |
|
714 |
671 |
$50K |
| 86762 |
|
5,608 |
5,062 |
$48K |
| 84702 |
|
5,416 |
3,954 |
$48K |
| 0052A |
|
1,141 |
1,115 |
$47K |
| 86146 |
|
601 |
548 |
$45K |
| 80076 |
|
5,953 |
5,578 |
$45K |
| 87088 |
|
4,153 |
3,895 |
$45K |
| 84146 |
|
3,411 |
3,142 |
$45K |
| 86901 |
|
10,081 |
9,221 |
$43K |
| 87536 |
|
570 |
535 |
$42K |
| 86160 |
|
2,459 |
2,298 |
$42K |
| 90480 |
|
1,092 |
1,092 |
$42K |
| 85652 |
|
15,454 |
14,469 |
$38K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
2,474 |
2,256 |
$38K |
| 0112A |
|
843 |
839 |
$36K |
| 82670 |
|
2,117 |
1,889 |
$34K |
| 86900 |
|
10,151 |
9,293 |
$34K |
| 0154A |
|
775 |
718 |
$33K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
656 |
581 |
$33K |
| 91321 |
|
820 |
817 |
$32K |
| 0064A |
|
806 |
794 |
$31K |
| 83002 |
|
2,934 |
2,662 |
$31K |
| 86769 |
|
752 |
679 |
$31K |
| 83020 |
|
3,281 |
3,203 |
$29K |
| 85610 |
|
7,923 |
6,617 |
$28K |
| 86225 |
|
2,483 |
2,305 |
$28K |
| 81003 |
|
13,407 |
12,258 |
$28K |
| 82950 |
|
5,964 |
5,676 |
$28K |
| 86147 |
|
649 |
588 |
$27K |
| 87070 |
|
4,209 |
3,986 |
$26K |
| 86696 |
|
1,235 |
1,218 |
$25K |
| 86431 |
|
3,518 |
3,279 |
$24K |
| 90686 |
|
1,345 |
1,042 |
$23K |
| 86735 |
|
1,849 |
1,721 |
$23K |
| 87493 |
|
527 |
496 |
$23K |
| 86200 |
|
2,120 |
2,102 |
$22K |
| 87338 |
|
1,162 |
1,109 |
$21K |
| 87517 |
|
411 |
384 |
$21K |
| 85046 |
|
3,930 |
3,572 |
$21K |
| 83615 |
|
3,766 |
3,310 |
$20K |
| 84270 |
|
1,276 |
1,249 |
$20K |
| 84100 |
|
4,618 |
4,052 |
$20K |
| 0074A |
|
462 |
462 |
$19K |
| 82533 |
|
1,506 |
1,299 |
$19K |
| 86364 |
|
2,481 |
2,326 |
$19K |
| 82627 |
|
1,437 |
1,381 |
$19K |
| 82951 |
|
1,472 |
1,430 |
$18K |
| 83516 |
|
1,534 |
1,382 |
$18K |
| 86695 |
|
1,171 |
1,155 |
$18K |
| 86334 |
|
803 |
738 |
$18K |
| 86800 |
|
1,520 |
1,461 |
$17K |
| 84550 |
|
4,332 |
3,966 |
$17K |
| 83690 |
|
2,615 |
2,439 |
$17K |
| 86376 |
|
1,929 |
1,853 |
$16K |
| 84165 |
|
1,757 |
1,635 |
$16K |
| 83525 |
|
1,735 |
1,711 |
$15K |
| 86336 |
|
708 |
652 |
$15K |
| 86665 |
|
428 |
395 |
$15K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
114 |
114 |
$15K |
| 85730 |
|
2,689 |
2,514 |
$14K |
| 82247 |
|
3,167 |
2,240 |
$14K |
| 82550 |
|
2,508 |
2,319 |
$14K |
| 0134A |
|
364 |
361 |
$14K |
| 82248 |
|
3,611 |
2,819 |
$14K |
| 86765 |
|
1,726 |
1,699 |
$14K |
| 88142 |
|
1,124 |
1,060 |
$14K |
| 86300 |
|
558 |
528 |
$13K |
| 84156 |
|
5,976 |
5,383 |
$13K |
| 80197 |
|
1,385 |
770 |
$13K |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
600 |
584 |
$13K |
| 86039 |
|
1,237 |
1,222 |
$13K |
| 83721 |
|
1,433 |
1,296 |
$13K |
| 84144 |
|
671 |
490 |
$12K |
| 82378 |
|
1,029 |
930 |
$12K |
| 0053A |
|
290 |
288 |
$12K |
| 0121A |
|
266 |
262 |
$11K |
| 84305 |
|
741 |
717 |
$11K |
| 83520 |
|
647 |
626 |
$11K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
32 |
16 |
$11K |
| 85018 |
|
4,369 |
4,222 |
$10K |
| 84460 |
|
2,054 |
1,926 |
$10K |
| 84703 |
|
1,364 |
1,264 |
$10K |
| 87449 |
|
634 |
590 |
$10K |
| 82677 |
|
673 |
617 |
$9K |
| 83521 |
|
573 |
533 |
$9K |
| 82652 |
|
435 |
381 |
$9K |
| 84450 |
|
1,991 |
1,870 |
$9K |
| 86360 |
|
350 |
337 |
$9K |
| 83498 |
|
556 |
539 |
$9K |
| 84402 |
|
449 |
438 |
$8K |
| 82565 |
|
1,911 |
1,826 |
$8K |
| 87522 |
Neg quan hep c or qual rna |
163 |
159 |
$8K |
| 85379 |
|
1,103 |
1,016 |
$8K |
| 82785 |
|
831 |
781 |
$8K |
| 84445 |
|
255 |
242 |
$8K |
| 84480 |
|
836 |
778 |
$8K |
| 87075 |
|
617 |
574 |
$7K |
| 0164A |
|
166 |
166 |
$7K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
51 |
51 |
$7K |
| 86304 |
|
344 |
302 |
$7K |
| 85014 |
|
3,069 |
2,951 |
$7K |
| 0081A |
|
167 |
165 |
$7K |
| 87045 |
|
583 |
544 |
$7K |
| 85390 |
|
772 |
700 |
$7K |
| 86705 |
|
471 |
436 |
$7K |
| 87209 |
|
446 |
425 |
$7K |
| 87427 |
|
539 |
503 |
$6K |
| 0073A |
|
153 |
150 |
$6K |
| 85245 |
|
446 |
405 |
$6K |
| 82150 |
|
1,023 |
938 |
$6K |
| 82397 |
|
454 |
433 |
$6K |
| 80177 |
|
691 |
670 |
$6K |
| 82610 |
|
572 |
521 |
$6K |
| 0003A |
|
171 |
126 |
$6K |
| 84425 |
|
474 |
473 |
$6K |
| 86359 |
|
294 |
280 |
$6K |
| 87205 |
|
1,683 |
1,573 |
$6K |
| 81025 |
|
1,090 |
964 |
$6K |
| 85613 |
|
716 |
650 |
$6K |
| 82977 |
|
1,122 |
1,049 |
$6K |
| 87521 |
Neg quan hep c or qual rna |
131 |
121 |
$5K |
| 0082A |
|
131 |
129 |
$5K |
| 82952 |
|
1,434 |
1,400 |
$5K |
| 84681 |
|
448 |
444 |
$5K |
| 83993 |
|
459 |
453 |
$5K |
| 0151A |
|
124 |
124 |
$5K |
| 85732 |
|
730 |
665 |
$5K |
| 86618 |
|
230 |
228 |
$5K |
| 36415 |
Collection of venous blood by venipuncture |
6,709 |
6,135 |
$5K |
| 80164 |
|
568 |
537 |
$5K |
| 85576 |
|
215 |
199 |
$5K |
| 84520 |
|
1,343 |
1,287 |
$5K |
| 80069 |
|
610 |
566 |
$4K |
| 83014 |
|
557 |
542 |
$4K |
| 84484 |
|
557 |
505 |
$4K |
| 85246 |
|
285 |
257 |
$4K |
| 87625 |
|
137 |
128 |
$4K |
| 82390 |
|
446 |
412 |
$4K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
55 |
55 |
$4K |
| 84466 |
|
434 |
387 |
$4K |
| 84630 |
|
379 |
374 |
$4K |
| 85670 |
|
790 |
715 |
$4K |
| 87046 |
|
640 |
600 |
$4K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
69 |
69 |
$3K |
| 86694 |
|
252 |
247 |
$3K |
| 88304 |
|
163 |
162 |
$3K |
| 87177 |
|
444 |
422 |
$3K |
| 87497 |
|
78 |
68 |
$3K |
| 82024 |
|
143 |
136 |
$3K |
| 0083A |
|
73 |
73 |
$3K |
| 84432 |
|
182 |
176 |
$3K |
| 86870 |
|
182 |
159 |
$3K |
| 90656 |
|
131 |
102 |
$3K |
| 82330 |
|
192 |
162 |
$2K |
| 88230 |
|
25 |
24 |
$2K |
| 86381 |
|
160 |
160 |
$2K |
| 86593 |
|
565 |
512 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
272 |
249 |
$2K |
| 84155 |
|
664 |
624 |
$2K |
| 82947 |
|
566 |
529 |
$2K |
| 0141A |
|
46 |
46 |
$2K |
| 85240 |
|
160 |
140 |
$2K |
| 86341 |
|
90 |
80 |
$2K |
| 86141 |
|
110 |
101 |
$2K |
| 86644 |
|
100 |
97 |
$2K |
| 86708 |
|
186 |
173 |
$2K |
| 85660 |
|
345 |
342 |
$2K |
| 82140 |
|
191 |
178 |
$2K |
| 87147 |
|
424 |
394 |
$1K |
| 0142A |
|
31 |
31 |
$1K |
| 84244 |
|
61 |
61 |
$1K |
| 86015 |
|
195 |
194 |
$1K |
| 82088 |
|
32 |
32 |
$1K |
| 82157 |
|
69 |
69 |
$1K |
| 82340 |
|
225 |
209 |
$1K |
| 84163 |
|
119 |
106 |
$1K |
| 99000 |
|
43 |
32 |
$1K |
| 87799 |
|
17 |
13 |
$972.79 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
76 |
62 |
$950.75 |
| 86361 |
|
61 |
54 |
$894.91 |
| 83718 |
|
118 |
112 |
$874.55 |
| 82747 |
|
62 |
60 |
$799.27 |
| 90662 |
|
23 |
22 |
$785.15 |
| 83630 |
|
66 |
63 |
$733.56 |
| 86258 |
|
78 |
70 |
$727.46 |
| 82465 |
|
165 |
144 |
$686.94 |
| 87102 |
|
105 |
95 |
$642.97 |
| 96127 |
|
36 |
32 |
$584.00 |
| 0013A |
|
13 |
13 |
$547.82 |
| 93793 |
|
183 |
65 |
$515.70 |
| 86645 |
|
29 |
27 |
$509.92 |
| 87077 |
|
816 |
753 |
$481.45 |
| 85247 |
|
34 |
27 |
$480.98 |
| 86677 |
|
32 |
30 |
$450.75 |
| 84166 |
|
49 |
45 |
$448.38 |
| 83010 |
|
51 |
46 |
$436.42 |
| 82103 |
|
42 |
41 |
$353.21 |
| 85384 |
|
57 |
41 |
$349.71 |
| 86709 |
|
54 |
51 |
$343.16 |
| 82525 |
|
31 |
31 |
$326.63 |
| 80178 |
|
50 |
43 |
$318.50 |
| 84436 |
|
43 |
41 |
$271.62 |
| 84080 |
|
27 |
26 |
$270.53 |
| 82310 |
|
60 |
59 |
$246.48 |
| 82164 |
|
28 |
26 |
$242.14 |
| 84145 |
|
14 |
14 |
$228.62 |
| 73610 |
|
15 |
13 |
$228.06 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
16 |
16 |
$197.54 |
| 87040 |
|
12 |
12 |
$189.00 |
| 82653 |
|
14 |
14 |
$179.14 |
| 84132 |
|
47 |
44 |
$170.71 |
| 83519 |
|
12 |
12 |
$169.09 |
| 87206 |
|
42 |
38 |
$168.39 |
| 86308 |
|
35 |
27 |
$168.00 |
| 83835 |
|
12 |
12 |
$158.16 |
| 85306 |
|
13 |
13 |
$119.40 |
| 85303 |
|
13 |
13 |
$118.03 |
| 86060 |
|
12 |
12 |
$103.20 |
| 80156 |
|
12 |
12 |
$93.84 |
| 87101 |
|
14 |
14 |
$86.80 |
| G0008 |
Administration of influenza virus vaccine |
12 |
12 |
$71.28 |
| 84075 |
|
13 |
12 |
$57.28 |
| 81002 |
|
15 |
15 |
$39.00 |